Nutraceuticals are gaining legitimacy and their potential clinical role is expanding. Data from 2017 provides evidence for their possible use in type 2 diabetes mellitus, the metabolic syndrome, obesity, dyslipidaemia and osteoporosis. Ongoing high-quality research in this area might justify future selective implementation of nutraceuticals into general health practice.
This is a preview of subscription content, log in via an institution to check access.
References
Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387–2397 (2015).
Marazzi, G. et al. Comparison of low-dose statin versus low-dose statin + armolipid plus in high-untensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE trial). Am. J. Cardiol. 120, 893–897 (2017).
Lloyd-Jones, D. M. et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J. Am. Coll. Cardiol. 70, 1785–1822 (2017).
Jamilian, M. & Asemi, Z. The effects of soy isoflavones on metabolic status of patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 101, 3386–3394 (2016).
Lambert, M. N. T. et al. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial. Am. J. Clin. Nutr. 106, 909–920 (2017).
Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333 (2002).
Nicolucci, A. C. et al. Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity. Gastroenterology 153, 711–722 (2017).
Comerford, K. B. Recent developments in multivitamin/mineral research. Adv. Nutr. 4, 644–656 (2013).
Dibaba, D. T. et al. The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 106, 921–929 (2017).
Kjaer, T. N. et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 102, 1642–1651 (2017).
Acknowledgements
A.J.B. is supported by the Clinical Investigator Program at the Schulich School of Medicine & Dentistry, Western University and by the Fernand Labrie Fellowship of the Canadian Society for Endocrinology. R.A.H. has received operating grants from the Canadian Institutes of Health Research (Foundation Grant), the Heart and Stroke Foundation of Ontario (G-15-0009214), and Genome Canada through Genome Quebec (award 4530).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.J.B. declares no competing interests. R.A.H. has received honoraria for membership on advisory boards and speakers' bureaus for Akcea/Ionis, Aegerion, Amgen, Gemphire, Regeneron, Sanofi and Valeant.
Rights and permissions
About this article
Cite this article
Berberich, A., Hegele, R. Nutraceuticals in endocrine disorders. Nat Rev Endocrinol 14, 68–70 (2018). https://doi.org/10.1038/nrendo.2017.169
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2017.169
- Springer Nature Limited